J. Emile, O. Abla, and S. Fraitag, Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages, Blood, vol.127, issue.22, pp.2672-2681, 2016.

J. Haroche, F. Cohen-aubart, and B. J. Rollins, Histiocytoses: emerging neoplasia behind inflammation, Lancet Oncol, vol.18, issue.2, pp.113-125, 2017.

J. Haroche, C. F. Arnaud, and L. , High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other nonLangerhans cell histiocytoses Brief report High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other nonLangerhans cell histiocytoses, Blood, vol.120, issue.13, pp.2700-2703, 2012.

H. Go, Y. K. Jeon, and J. Huh, Frequent detection of BRAF V 600E mutations in histiocytic and dendritic cell neoplasms, Histopathology, vol.65, issue.2, pp.261-272, 2014.

R. Chakraborty, O. A. Hampton, and X. Shen, Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis, Blood, vol.124, pp.3007-3015, 2014.

J. Haroche, F. Cohen-aubart, and E. , Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation, Blood, vol.121, issue.9, pp.1495-1500, 2013.

D. M. Hyman, I. Puzanov, and V. Subbiah, Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations, N Engl J Med, vol.373, issue.8, pp.726-736, 2015.

J. Emile, E. L. Diamond, and Z. Helias-rodzewicz, Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease, Blood, vol.124, pp.3016-3019, 2014.

E. L. Diamond, B. H. Durham, and J. Haroche, Diverse and targetable kinase alterations drive histiocytic neoplasms, Cancer Discov, vol.6, issue.2, pp.154-165, 2016.

L. H. Lee, A. Gasilina, and J. Roychoudhury, Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes, JCI Insight, vol.2, issue.3, p.89473, 2017.

S. Garces, L. J. Medeiros, and K. P. Patel, Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease, Mod Pathol, vol.30, issue.10, pp.1367-1377, 2017.

M. S. Matter, M. Bihl, D. Juskevicius, and A. Tzankov, Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease, Virchows Arch, vol.471, issue.4, pp.545-547, 2017.

E. Jacobsen, V. Shanmugam, and J. Jagannathan, Rosai-Dorfman disease with activating KRAS mutation -response to cobimetinib, N Engl J Med, vol.377, issue.24, pp.2398-2399, 2017.

C. E. Allen, S. Ladisch, and K. L. Mcclain, How I treat Langerhans cell histiocytosis, Blood, vol.126, issue.1, pp.26-35, 2015.

M. Chilosi, F. Facchetti, and A. Caliò, Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and nonpulmonary Langerhans cell histiocytosis, Leuk Lymphoma, vol.55, issue.11, pp.2620-2626, 2014.